Remote Ischemic Preconditioning To Reduce Contrast-Induced Nephropathy: A Randomized Controlled Trial
Publication year
2015Source
European Journal of Vascular and Endovascular Surgery, 50, 4, (2015), pp. 527-32ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Surgery
Nephrology
Health Evidence
Medical Imaging
Journal title
European Journal of Vascular and Endovascular Surgery
Volume
vol. 50
Issue
iss. 4
Page start
p. 527
Page end
p. 32
Subject
Radboudumc 0: Other Research RIHS: Radboud Institute for Health Sciences; Radboudumc 10: Reconstructive and regenerative medicine RIHS: Radboud Institute for Health Sciences; Radboudumc 11: Renal disorders RIHS: Radboud Institute for Health Sciences; Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health SciencesAbstract
BACKGROUND: Despite the increasing use of pre- and post-hydration protocols and low osmolar instead of high osmolar iodine containing contrast media, the incidence of contrast induced nephropathy (CIN) is still significant. There is evidence that contrast media cause ischemia reperfusion injury of the renal medulla. Remote ischemic preconditioning (RIPC) is a non-invasive, safe, and low cost method to reduce ischemia reperfusion injury. The aim of this study is to investigate whether RIPC, as an adjunct to standard preventive measures, reduces contrast induced acute kidney injury in patients at risk of CIN. METHODS: The RIPCIN study is a multicenter, single blinded, randomized controlled trial in which 76 patients at risk of CIN received standard hydration combined with RIPC or hydration with sham preconditioning. RIPC was applied by four cycles of 5 min ischemia and 5 min reperfusion of the forearm. The primary outcome measure was the change in serum creatinine from baseline to 48 to 72 hours after contrast administration. RESULTS: With regard to the primary endpoint, no significant effect of RIPC was found. CIN occurred in four patients (2 sham and 2 RIPC). A pre-defined subgroup analysis of patients with a Mehran risk score >/=11, showed a significantly reduced change in serum creatinine from baseline to 48 to 72 hours in patients allocated to the RIPC group (Delta creatinine -3.3 +/- 9.8 mumol/L) compared with the sham group (Delta creatinine +17.8 +/- 20.1 mumol/L). CONCLUSION: RIPC, as an adjunct to standard preventive measures, does not improve serum creatinine levels after contrast administration in patients at risk of CIN according to the Dutch guideline. However, the present data indicate that RIPC might have beneficial effects in patients at a high or very high risk of CIN (Mehran score >/= 11). The RIPCIN study is registered at: http://www.controlled-trials.com/ISRCTN76496973.
This item appears in the following Collection(s)
- Academic publications [247994]
- Faculty of Medical Sciences [93946]
Upload full text
Use your RU or RadboudUMC credentials to log in with SURFconext to upload a file for processing by the repository team.